ContraFect : Lysin CF-370 Exhibits Broad Spectrum Antimicrobial Activity Against Gram-Negative (GN) ESKAPE Pathogens

Lysin CF-370 Exhibits Broad Spectrum Antimicrobial Activity Against Gram-Negative (GN) ESKAPE Pathogens

Raymond Schuch, Ph.D.

ContraFect Corporation

Yonkers, New York

New Agents Discovery Summary Session: Early New Antimicrobial Agents June 21, 2021

11:50-12:05

worldmicrobeforum.org | 1

Forward Looking Statements

This presentation contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believe," "expect," "target", "anticipate," "estimate," "intend," "plan," "proposed", "potential" or similar references to future periods. Examples of forward-looking statements in this presentation include, without limitation, statements made regarding ContraFect Corporation's ("ContraFect") ability to develop DLAs as new medical modalities for the treatment of life-threatening,antibiotic-resistant infections, cited information, ContraFect's End-of Phase 2 meeting with the FDA, Phase 3 plans, designs and timing, Phase 2 study results, data analyses and comparisons, health economic data, safety and efficacy of exebacase, exebacase's value proposition, patent protection, commercial assessments, in vitro and in vivo study results, ContraFect's plans regarding its next IND and extrapolated data. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, proposals, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward- looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and other filings with the Securities and Exchange Commission ("SEC"). Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection. Any forward-looking statement made by ContraFect in this presentation is based only on information currently available and speaks only as of the date on which it is made. No representation or warranty is made as to the completeness or accuracy of the information provided in this presentation. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Audiences are cautioned that forward-looking statements or similar information are not guarantees of future performance and, accordingly, are expressly cautioned not to put undue reliance on forward-looking statements or similar information due to the inherent uncertainty therein.

worldmicrobeforum.org | 2

ContraFect is a late clinical-stage biotechnology company leading the development of direct lytic agents (DLAs), which include lysins and amurin peptides, as new medical modalities for the treatment of life- threatening and antibiotic-resistant infections

Lysins: Novel Antimicrobial Modalities

		LYSIN THERAPY
	PHAGE LIFECYCLE	1. Add recombinant lysin
1.	Infection
		2.Lysis "from without"
2.	Replication (lysin synthesis)

Lysin =

3. Lysin activity releases phage

MOA: Peptidoglycan Hydrolysis

Core Microbiologic Features*

Rapid, potent bactericidal activity

Eradicates biofilm

Synergy with standard of care antibiotics

Low propensity of resistance

Antibiotic rensensitization

Extended postantibiotic/sub-MIC effects

worldmicrobeforum.org | 4

*PMID: 24286983, 30670427, 28461319, 31712212

ContraFect Direct Lytic Agent Platform

Exebacase: First-in-Class Lysin Candidate

• 26 kDa modular bacterial cell wall hydrolase enzyme
• Highly potent against Staphylococcus aureus and unique lysis and eradication of biofilms
• Potent synergy with broad range of anti-staphylococcal antibiotics

Exebacase clinical-stage program

• Advancing with FDA Breakthrough Therapy designation
• Ongoing Phase 3 DISRUPT superiority trial
• Completed Phase 2 superiority study with positive results
• • Significant improvement in MRSA patient responder rates with over 40% increase over standard-of-care antibiotics alone
  • Demonstrated favorable safety and tolerability data in patients

Broad pipeline of new agents

• Second generation antistaphylococcal lysin
• Novel phage-derived lytic agents targeting a broad range of GN pathogens (ESKAPE)

worldmicrobeforum.org | 5